Press Release

Illumina to Announce Second Quarter 2017 Financial Results on Tuesday, August 1, 2017

SAN DIEGO--(BUSINESS WIRE)--Jul. 11, 2017-- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for second quarter 2017 following the close of market on Tuesday, August 1, 2017.

On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, Marc Stapley, Executive Vice President and Chief Administrative Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Tuesday, August 1, 2017. Interested parties may listen to the call by dialing 888.771.4371 (passcode: 45213860), or if outside North America by dialing +1.847.585.4405 (passcode: 45213860). Individuals may access the live teleconference in the Investor Relations section of Illumina’s web site under the “company” tab at www.illumina.com.

A replay of the conference call will be available from 4:00 pm Pacific Time (7:00 pm Eastern Time) on August 1, 2017 through August 8, 2017 by dialing 888.843.7419 (passcode: 45213860), or if outside North America by dialing +1.630.652.3042 (passcode: 45213860).

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers
858.255.5243
ir@illumina.com
or
Media:
Eric Endicott
858.882.6822
pr@illumina.com

Recent Articles

When CGP uncovers potential hereditary cancer risk
When CGP uncovers potential hereditary cancer risk
Early access users rave about Illumina’s new MiSeq i100 Series
Early access users rave about Illumina’s new MiSeq i100 Series
Trailblazing study shows early CGP leads to better precision treatments
Trailblazing study shows early CGP leads to better precision treatments